阿洛司琼与安慰剂对照治疗女性腹泻型肠易激综合征的临床证据  

Clinical Evidence of Alosetron vs Placebo in Treatment of Women with Diarrhea-Predominant Irritable Bowel Syndrome

作　　者：冉红梅[1] 王一平[1] 

机构地区：[1]四川大学华西医院消化内科,四川成都610041

出　　处：《华西医学》2007年第3期461-462,共2页West China Medical Journal

摘　　要：目的：对于5-HT3受体拮抗剂阿洛司琼治疗女性腹泻型肠易激综合征,进行了证据检索和评价,为临床医生和患者提供最新的临床证据。方法：计算机检索Pubmed（1996～2006）和Cochrane图书馆（2006年第三期）,查找阿洛司琼与安慰剂对照治疗女性腹泻型肠易激综合征的随机对照试验、系统评价和Meta分析,并对所搜集的证据进行评价。结果：高质量的临床证据表明,阿洛司琼治疗女性腹泻型肠易激综合征的近期及远期疗效均优于安慰剂,便秘是最常见的不良反应,严重不良反应发生率低,患者对于阿洛司琼治疗的满意度和健康相关生存质量均优于安慰剂。结论：阿洛司琼治疗女性腹泻型肠易激综合征安全、有效,遵循个体化原则,予以临床应用。Objective： To find clinical evidence of alosetmn vs placebo in treatment of women with diarrhea - predominant irritable bowel syndrome. Methods： We attempted to get the evidence of alosetron in the treatment of women with diarrhea- predominant irritable bowel syndrome by searching Pubmed （1996 - 2006） and The Cochrane Library （issue 3, 2006） and appraised evidence. Results： We found that alosetmn was more effective than placebo in the treatment of women with diarrhea - pre- dominant irritable bowel syndrome and have better long - term efficacy. Constipation was the most common side effect. Serious adverse event of alosetmn is rare. Patients treated with alsetron had more satisfaction and better quality of life than those of placebo. Conclusion： We should use alosetmn to treat women with diarrhea- predominant irritabl bowel syndrome by applying clinical evidence and according to the principle of individuation.

关 键 词：女性腹泻型肠易激综合征 阿洛司琼 临床证据 随机对照试验 

分 类 号：R574[医药卫生—消化系统]